Effect of cardiopulmonary bypass on fentanyl distribution and elimination

Adolph Koska, A. Romagnoli, W. G. Kramer

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Fentanyl kinetics was studied in two groups of six patients, one group undergoing surgery with and one without cardiopulmonary bypass; the latter served as the controls. Plasma fentanyl concentrations declined biexponentially in the control patients with an average half-life (t̄β) of 3.3 ± 1.1 hr, total plasma clearance of 11.2 ± 3.4 ml/min/kg, and volume of distribution (Vdβ) of 3.2 ± 1.5 l/kg. The plasma concentration/time curves were severely disrupted during cardiopulmonary bypass but appeared to regain a log-linear decay once bypass was complete. This elimination phase had a (t 1/2 ) of 5.2 ± 2.7 hr, longer than that in the control patients. Since fentanyl is eliminated primarily by hepatic metabolism, decreased liver plasma flow observed during and after bypass, as evidenced by a 30% decrease in indocyanine green clearance, may contribute to the extended (t 1/2 ). The prolonged (t 1/2 ) has clinical importance because of potentially prolonged effects and their relation to other drugs and the clinical management of the patient.

Original languageEnglish (US)
Pages (from-to)100-105
Number of pages6
JournalClinical Pharmacology and Therapeutics
Volume29
Issue number1
StatePublished - 1981
Externally publishedYes

Fingerprint

Fentanyl
Cardiopulmonary Bypass
Indocyanine Green
Liver
Half-Life
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology

Cite this

Effect of cardiopulmonary bypass on fentanyl distribution and elimination. / Koska, Adolph; Romagnoli, A.; Kramer, W. G.

In: Clinical Pharmacology and Therapeutics, Vol. 29, No. 1, 1981, p. 100-105.

Research output: Contribution to journalArticle

Koska, A, Romagnoli, A & Kramer, WG 1981, 'Effect of cardiopulmonary bypass on fentanyl distribution and elimination', Clinical Pharmacology and Therapeutics, vol. 29, no. 1, pp. 100-105.
Koska, Adolph ; Romagnoli, A. ; Kramer, W. G. / Effect of cardiopulmonary bypass on fentanyl distribution and elimination. In: Clinical Pharmacology and Therapeutics. 1981 ; Vol. 29, No. 1. pp. 100-105.
@article{4937de942fc84778aca39d2c10378c40,
title = "Effect of cardiopulmonary bypass on fentanyl distribution and elimination",
abstract = "Fentanyl kinetics was studied in two groups of six patients, one group undergoing surgery with and one without cardiopulmonary bypass; the latter served as the controls. Plasma fentanyl concentrations declined biexponentially in the control patients with an average half-life (t̄β) of 3.3 ± 1.1 hr, total plasma clearance of 11.2 ± 3.4 ml/min/kg, and volume of distribution (Vdβ) of 3.2 ± 1.5 l/kg. The plasma concentration/time curves were severely disrupted during cardiopulmonary bypass but appeared to regain a log-linear decay once bypass was complete. This elimination phase had a (t 1/2 ) of 5.2 ± 2.7 hr, longer than that in the control patients. Since fentanyl is eliminated primarily by hepatic metabolism, decreased liver plasma flow observed during and after bypass, as evidenced by a 30{\%} decrease in indocyanine green clearance, may contribute to the extended (t 1/2 ). The prolonged (t 1/2 ) has clinical importance because of potentially prolonged effects and their relation to other drugs and the clinical management of the patient.",
author = "Adolph Koska and A. Romagnoli and Kramer, {W. G.}",
year = "1981",
language = "English (US)",
volume = "29",
pages = "100--105",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Effect of cardiopulmonary bypass on fentanyl distribution and elimination

AU - Koska, Adolph

AU - Romagnoli, A.

AU - Kramer, W. G.

PY - 1981

Y1 - 1981

N2 - Fentanyl kinetics was studied in two groups of six patients, one group undergoing surgery with and one without cardiopulmonary bypass; the latter served as the controls. Plasma fentanyl concentrations declined biexponentially in the control patients with an average half-life (t̄β) of 3.3 ± 1.1 hr, total plasma clearance of 11.2 ± 3.4 ml/min/kg, and volume of distribution (Vdβ) of 3.2 ± 1.5 l/kg. The plasma concentration/time curves were severely disrupted during cardiopulmonary bypass but appeared to regain a log-linear decay once bypass was complete. This elimination phase had a (t 1/2 ) of 5.2 ± 2.7 hr, longer than that in the control patients. Since fentanyl is eliminated primarily by hepatic metabolism, decreased liver plasma flow observed during and after bypass, as evidenced by a 30% decrease in indocyanine green clearance, may contribute to the extended (t 1/2 ). The prolonged (t 1/2 ) has clinical importance because of potentially prolonged effects and their relation to other drugs and the clinical management of the patient.

AB - Fentanyl kinetics was studied in two groups of six patients, one group undergoing surgery with and one without cardiopulmonary bypass; the latter served as the controls. Plasma fentanyl concentrations declined biexponentially in the control patients with an average half-life (t̄β) of 3.3 ± 1.1 hr, total plasma clearance of 11.2 ± 3.4 ml/min/kg, and volume of distribution (Vdβ) of 3.2 ± 1.5 l/kg. The plasma concentration/time curves were severely disrupted during cardiopulmonary bypass but appeared to regain a log-linear decay once bypass was complete. This elimination phase had a (t 1/2 ) of 5.2 ± 2.7 hr, longer than that in the control patients. Since fentanyl is eliminated primarily by hepatic metabolism, decreased liver plasma flow observed during and after bypass, as evidenced by a 30% decrease in indocyanine green clearance, may contribute to the extended (t 1/2 ). The prolonged (t 1/2 ) has clinical importance because of potentially prolonged effects and their relation to other drugs and the clinical management of the patient.

UR - http://www.scopus.com/inward/record.url?scp=0019474698&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019474698&partnerID=8YFLogxK

M3 - Article

C2 - 6970110

AN - SCOPUS:0019474698

VL - 29

SP - 100

EP - 105

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 1

ER -